Patients with NIPC Patients without NIPC (n=20) (n=101) Age, median (range), y 35 (16-54) 35 (15-55) Sex, n Male 13 59 Female 7 42 Diagnosis,n CML  6 32 AML 9 26 ALL 2 21 MDS 1 10 AA 2 12 Conditioning, n CA+CY 3 35 BU+CY 10 33 BU+ML 3 8 ML 0 10 CY 4 15 TBI dose, n 12Gy≥ 6 37 10Gy≥ 7 45 5Gy≥ 3 13 non TBI/TLI 4 6 Acute GVHD, n 0~I 15 87 II~IV 5 14

CML: Chronic Myeloid Leukemia; AML: Acute Myeloblastic Leukemia; ALL: Acute Lymphoblastic Leukemia; MDS: Myelodysplastic Syndrome; AA: Aplastic Anemia; CA: Cyclophosphamide; CA: Cytarabine; BU: Busulphan; ML: Melphalan; TBI: Total Body Irradiation. Patients with and without NIPC did not differ significantly with respect to age, sex, underlying disease, or conditioning regimen.

Table 1: Patients characteristics.